Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies
Christine Birdwell, Warren Fiskus, Tapan M. Kadia, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 3
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research
Rafał Skopek, Małgorzata Palusińska, Katarzyna Barbara Kaczor-Keller, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5377-5377
Open Access | Times Cited: 41
GNL3L exhibits pro-tumor activities via NF-κB pathway as a poor prognostic factor in acute myeloid leukemia
Li Ji, Zhimin Wu, Yipeng Pan, et al.
Journal of Cancer (2024) Vol. 15, Iss. 13, pp. 4072-4080
Open Access | Times Cited: 15
PRMT5 regulates ATF4 transcript splicing and oxidative stress response
Magdalena M. Szewczyk, Genna M. Luciani, Victoria Vu, et al.
Redox Biology (2022) Vol. 51, pp. 102282-102282
Open Access | Times Cited: 25
RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia
S Gialesaki, Daniela Bräuer-Hartmann, H Issa, et al.
Blood (2022) Vol. 141, Iss. 10, pp. 1105-1118
Open Access | Times Cited: 24
Regulation and Functions of α6-Integrin (CD49f) in Cancer Biology
Rahele Khademi, Hossein Malekzadeh, Sara Bahrami, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3466-3466
Open Access | Times Cited: 15
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)
Guillaume Richard‐Carpentier, Caitlin R. Rausch, Koji Sasaki, et al.
Haematologica (2023)
Open Access | Times Cited: 14
Fate and state transitions during human blood vessel organoid development
Marina Nikolova, Zhisong He, Reiner Wimmer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer
Yongheng Chen, Ying Ying, Maolin Wang, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 11
Recent Advances Towards the Understanding of Secondary Acute Myeloid Leukemia Progression
Scott S. Auerbach, Beana Puka, Upendarrao Golla, et al.
(2024)
Open Access | Times Cited: 4
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials
Jasna Metović, Yedda Li, Yi Gong, et al.
Neurotherapeutics (2024) Vol. 21, Iss. 4, pp. e00443-e00443
Open Access | Times Cited: 4
The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression
Xiaohang Ma, Mengge Gao, Riyan Cheng, et al.
Cancer Letters (2025) Vol. 615, pp. 217547-217547
Closed Access
Case Report: Decitabine and venetoclax sequentially followed by FLAG-Ida and venetoclax with immediate allogeneic stem cell transplantation in newly diagnosed acute myeloid leukemia with chromosome 3 inversion/MECOM rearrangement
Andrius Žučenka, Milvydė Tamutytė
Frontiers in Oncology (2025) Vol. 15
Open Access
REDD1/DDIT4 counteracts endoplasmic reticulum stress-induced apoptosis by controlling the expression of death receptor TRAILR2/DR5 in cancer cells
Rocío Mora-Molina, Younes El Yousfi, Cathrin Hagenlocher, et al.
Research Square (Research Square) (2025)
Closed Access
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia
Atsushi Tanaka, Taizo A. Nakano, Masaki Nomura, et al.
Blood (2022) Vol. 140, Iss. 8, pp. 875-888
Open Access | Times Cited: 15
Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics
Nicole Santoro, Prassede Salutari, Mauro Di Ianni, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4259-4259
Open Access | Times Cited: 3
The microprotein HDSP promotes gastric cancer progression through activating the MECOM-SPINK1-EGFR signaling axis
Yuli Chen, Qiuhui Li, Xiang Yu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Identification of transcription factors dictating blood cell development using a bidirectional transcription network-based computational framework
Branco M. H. Heuts, Saioa Arza-Apalategi, Siebren Frölich, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 13
Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression
Scott S. Auerbach, Beana Puka, Upendarrao Golla, et al.
Life (2024) Vol. 14, Iss. 3, pp. 309-309
Open Access | Times Cited: 2
MECOM: a Bioinformatics and Experimentally Identified Marker for the Diagnosis and Prognosis of Lung Adenocarcinoma
Anqi Li, Meng Li, Jing Wang, et al.
Biomarkers in Medicine (2024) Vol. 18, Iss. 2, pp. 79-91
Closed Access | Times Cited: 2
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia
Hiroki Akiyama, Hagop Kantarjian, Elias Jabbour, et al.
International Journal of Hematology (2024) Vol. 120, Iss. 2, pp. 203-211
Closed Access | Times Cited: 2
An activity-regulated transcriptional program directly drives synaptogenesis
Callista Yee, Yutong Xiao, Hongwen Chen, et al.
Nature Neuroscience (2024) Vol. 27, Iss. 9, pp. 1695-1707
Open Access | Times Cited: 2
Mecom mutation related to radioulnar synostosis with amegakaryocytic thrombocytopenia reduces HSPCs in mice
Koki Nagai, Tetsuya Niihori, Akihiko Muto, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5409-5420
Open Access | Times Cited: 5
Suppressing crucial oncogenes of leukemia initiator cells by major royal jelly protein 2 for mediating apoptosis in myeloid and lymphoid leukemia cells
Marwa M. Abu‐Serie, Noha H. Habashy
Food & Function (2022) Vol. 13, Iss. 17, pp. 8951-8966
Closed Access | Times Cited: 9
Transcription factor genetics and biology in predisposition to bone marrow failure and hematological malignancy
Jiarna R. Zerella, Claire C. Homan, Peer Arts, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)
Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top